AX9 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Akebia Therapeutics Inc

Watchlist Manager

Watchlist

Price: 1.124 EUR -1.45% Market Closed

Market Cap: €374.3m

A	Akebia Therapeutics Inc SWB:AX9	US
B	Biogen Inc DUS:IDP	US
	Akamai Technologies Inc NASDAQ:AKAM	US
	WuXi Biologics (Cayman) Inc OTC:WXIBF	CN
	Visa Inc NYSE:V	US
E	ESCO Technologies Inc F:ET7	US
S	Sinopec Oilfield Service Corp XMUN:YIZH	CN
A	Asahi Intecc Co Ltd F:6XT	JP
L	Lime Technologies AB (publ) F:LTX	SE
P	Panasonic Holdings Corp DUS:MAT1	JP

Profitability Summary

Akebia Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

82%

Strong 3Y Average Gross Margin

83%

Gross Margin is Increasing

80% > 82%

Negative Operating Margin

-3%

Negative 3Y Average Operating Margin

-10%

Operating Margin is Increasing

-46% > -3%

Negative Net Margin

-14%

Negative 3Y Average Net Margin

-21%

Net Margin is Increasing

-51% > -14%

Exceptional Free Cash Flow Margin

13%

Negative 3Y Average Free Cash Flow Margin

-7%

Free Cash Flow Margin is Increasing

-17% > 13%

Negative ROE

-109%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-8%

ROIC is Increasing

-34% > -3%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.